Abstract
Background: The treatment of metastatic melanoma (MM) has been dramatically improved through the use of BRAF and MEK inhibitors in patients whose tumors harbor activating mutations in BRAF. However, these mutations occur in only ∼50% of MMs and a targeted therapy(ies) has yet to be identified for those MMs that contain wild-type (WT) BRAF. Using The Cancer Genome Atlas melanoma (TCGA-SKCM) dataset, we discovered that 20% of BRAF WT melanomas harbor a missense mutation in ERBB4, which encodes a member of the epidermal growth factor receptor (EGFR/ ErbB1) family of receptor tyrosine kinases. Hence, our goal is to evaluate whether ERBB4 mutant alleles function as biomarkers and targets for therapeutic intervention in BRAF WT MMs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.